A phase II study (ANDANTE I) aimed to evaluate the efficacy and safety of PF-04236921 in patients with moderate-to-severe CD who had inadequately responded to anti-TNF therapy (Danese et al., 2019). This evidence concerns the gene TNF and Cowden disease.